VioQuest begins clinical trials for anti-cancer compound VQD-002

By E. Janene Geiss

Philadelphia, Jan. 9 - VioQuest Pharmaceuticals said Monday that it will initiate clinical trials in the first quarter of 2006 for VQD-002, Triciribine-Phosphate (TCN-P), an anti-cancer compound with a unique mechanism of action.

VQD-002, a targeted tricyclic nucleoside under development at the Moffitt Cancer Center in Tampa, Fla., has been shown in preclinical studies to significantly inhibit tumor growth in breast, ovarian, colorectal, pancreatic and other cancers where abnormal levels of phosphorylated Akt (protein kinase B) have been observed, according to a company news release.

"VQD-002 has shown great promise as a targeted therapeutic during preclinical trials at Moffitt, and we are ready to move this drug into the next phase," VioQuest's chief executive officer Daniel Greenleaf said in the release.

VioQuest is a Monmouth Junction, N.J., pharmaceutical company that acquires, develops and commercializes targeted late-preclinical and early clinical-stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.